{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:13:01Z","timestamp":1778584381581,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011471","name":"Shanghai Minhang Health And Family Planning Commission","doi-asserted-by":"publisher","award":["20184Y0022"],"award-info":[{"award-number":["20184Y0022"]}],"id":[{"id":"10.13039\/501100011471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011471","name":"Shanghai Minhang Health And Family Planning Commission","doi-asserted-by":"publisher","award":["20194Y0007"],"award-info":[{"award-number":["20194Y0007"]}],"id":[{"id":"10.13039\/501100011471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011471","name":"Shanghai Minhang Health And Family Planning Commission","doi-asserted-by":"publisher","award":["PY2018-III-06"],"award-info":[{"award-number":["PY2018-III-06"]}],"id":[{"id":"10.13039\/501100011471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["JDYX2020KYZX009"],"award-info":[{"award-number":["JDYX2020KYZX009"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.phrs.2020.104872","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T13:13:04Z","timestamp":1588252384000},"page":"104872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-8644","authenticated-orcid":false,"given":"Han","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zai-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Jia","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Tian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hou-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104872_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2020.104872_bib0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"Journal of medical virology"},{"key":"10.1016\/j.phrs.2020.104872_bib0015","first-page":"1","article-title":"Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity","author":"Shanshal","year":"2020","journal-title":"The Journal of dermatological treatment"},{"issue":"20","key":"10.1016\/j.phrs.2020.104872_bib0020","first-page":"30390","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"S0883-9441","author":"Cortegiani","year":"2020","journal-title":"Journal of critical care"},{"issue":"1","key":"10.1016\/j.phrs.2020.104872_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Bioscience trends"},{"issue":"10223","key":"10.1016\/j.phrs.2020.104872_bib0030","first-page":"497","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Zhu","year":"2020","journal-title":"Emerging microbes & infections"},{"issue":"11","key":"10.1016\/j.phrs.2020.104872_bib0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.phrs.2020.104872_bib0040","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1365-3156.2004.01281.x","article-title":"Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003","volume":"9","author":"Leong","year":"2004","journal-title":"Tropical medicine & international health: TM & IH"},{"issue":"3","key":"10.1016\/j.phrs.2020.104872_bib0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.phrs.2020.104872_bib0050","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong medical journal = Xianggang yi xue za zhi"},{"issue":"3","key":"10.1016\/j.phrs.2020.104872_bib0055","first-page":"211","article-title":"A field trial for evaluating the safety of recombinant human interferon alpha-2b for nasal spray","volume":"19","author":"Chen","year":"2005","journal-title":"Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology"},{"issue":"24","key":"10.1016\/j.phrs.2020.104872_bib0060","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","article-title":"Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study","volume":"290","author":"Loutfy","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2020.104872_bib0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.phrs.2020.104872_bib0070","first-page":"72","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"396","key":"10.1016\/j.phrs.2020.104872_bib0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Science translational medicine"},{"issue":"4","key":"10.1016\/j.phrs.2020.104872_bib0080","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Voprosy virusologii"},{"key":"10.1016\/j.phrs.2020.104872_bib0085","series-title":"Potential Interventions for Novel Coronavirus in China: A Systematic Review","author":"Zhang","year":"2020"},{"key":"10.1016\/j.phrs.2020.104872_bib0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tmaid.2019.06.012","article-title":"A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","volume":"30","author":"Momattin","year":"2019","journal-title":"Travel medicine and infectious disease"},{"issue":"10","key":"10.1016\/j.phrs.2020.104872_bib0095","doi-asserted-by":"crossref","first-page":"e792","DOI":"10.1016\/j.ijid.2013.07.002","article-title":"Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy","volume":"17","author":"Momattin","year":"2013","journal-title":"International journal of infectious diseases: IJID"},{"issue":"3","key":"10.1016\/j.phrs.2020.104872_bib0100","first-page":"e1977","article-title":"Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis","volume":"28","author":"Morra","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.phrs.2020.104872_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option","author":"Yao","year":"2020","journal-title":"Journal of medical virology"},{"key":"10.1016\/j.phrs.2020.104872_bib0110","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.phrs.2020.104872_bib0115","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells GA","year":"2020"},{"key":"10.1016\/j.phrs.2020.104872_bib0120","series-title":"GRADEpro. [Computer program]. Version 3.2 for Windows","author":"Jan","year":"2008"},{"issue":"7414","key":"10.1016\/j.phrs.2020.104872_bib0125","first-page":"557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed.)"},{"issue":"4","key":"10.1016\/j.phrs.2020.104872_bib0130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1592\/phco.27.4.494","article-title":"Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome","volume":"27","author":"Muller","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"20","key":"10.1016\/j.phrs.2020.104872_bib0135","first-page":"30113","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: A retrospective cohort study","volume":"S0163-4453","author":"Deng","year":"2020","journal-title":"The Journal of infection"},{"key":"10.1016\/j.phrs.2020.104872_bib0140","series-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020"},{"issue":"11","key":"10.1016\/j.phrs.2020.104872_bib0145","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study","volume":"14","author":"Omrani","year":"2014","journal-title":"The Lancet Infectious Diseases"},{"issue":"2","key":"10.1016\/j.phrs.2020.104872_bib0150","first-page":"109","article-title":"Clinical study of interferon-\u03b1 for SARS patient","volume":"21","author":"Li","year":"2005","journal-title":"Clinical Medicine of China"},{"issue":"12","key":"10.1016\/j.phrs.2020.104872_bib0155","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.amjmed.2009.07.018","article-title":"Effectiveness of ribavirin and corticosteroids for severe acute respiratory syndrome","volume":"122","author":"Lau","year":"2009","journal-title":"The American journal of medicine"},{"key":"10.1016\/j.phrs.2020.104872_bib0160","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"International journal of antimicrobial agents"},{"issue":"003","key":"10.1016\/j.phrs.2020.104872_bib0165","first-page":"154","article-title":"The case-control study of relationship between ribavirin therapy and bradycardia in SARS patients","volume":"006","author":"Fu","year":"2004","journal-title":"ADR"},{"issue":"6","key":"10.1016\/j.phrs.2020.104872_bib0170","first-page":"410","article-title":"Analysis of the Effect of Different SARS Anti-virus Treatment Drugs","volume":"19","author":"Fu","year":"2003","journal-title":"Pharm J Chin PLA"},{"issue":"3","key":"10.1016\/j.phrs.2020.104872_bib0175","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2020.104872_bib0180","article-title":"Efficacies of lopinavir\/ritonavir and abidol in the treatment of novel coronavirus pneumonia","volume":"38","author":"Chen","year":"2020","journal-title":"Chinese journal of infectious disease"},{"issue":"1","key":"10.1016\/j.phrs.2020.104872_bib0185","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","volume":"49","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ (Med Sci)"},{"key":"10.1016\/j.phrs.2020.104872_bib0190","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","author":"Cao","year":"2020","journal-title":"The New England journal of medicine"},{"issue":"9","key":"10.1016\/j.phrs.2020.104872_bib0195","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","article-title":"Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study","volume":"70","author":"Arabi","year":"2019","journal-title":"Clinical infectious diseases"},{"key":"10.1016\/j.phrs.2020.104872_bib0200","series-title":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial","author":"Tang","year":"2020"},{"issue":"Pt 8","key":"10.1016\/j.phrs.2020.104872_bib0205","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1099\/jmm.0.05320-0","article-title":"Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China","volume":"52","author":"Zhao","year":"2003","journal-title":"Journal of medical microbiology"},{"key":"10.1016\/j.phrs.2020.104872_bib0210","series-title":"Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review","author":"Kapoor","year":"2020"},{"key":"10.1016\/j.phrs.2020.104872_bib0215","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clinical infectious diseases"},{"issue":"3","key":"10.1016\/j.phrs.2020.104872_bib0220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell research"},{"key":"10.1016\/j.phrs.2020.104872_bib0225","series-title":"Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients","author":"Liu","year":"2020"},{"key":"10.1016\/j.phrs.2020.104872_bib0230","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101068","article-title":"Ready for a long fight against the COVID-19 outbreak: an innovative model of tiered primary health care in Taiwan","author":"Chang","year":"2020","journal-title":"BJGP open"},{"issue":"8","key":"10.1016\/j.phrs.2020.104872_bib0235","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.phrs.2020.104872_bib0240","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral research"},{"issue":"12","key":"10.1016\/j.phrs.2020.104872_bib0245","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"8","key":"10.1016\/j.phrs.2020.104872_bib0250","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1128\/AAC.00315-13","article-title":"Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients","volume":"57","author":"Lopez-Cortes","year":"2013","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"10.1016\/j.phrs.2020.104872_bib0255","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","author":"Elfiky","year":"2020","journal-title":"Life sciences"},{"issue":"4","key":"10.1016\/j.phrs.2020.104872_bib0260","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Shuster","year":"2008","journal-title":"Voprosy virusologii"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:32:09Z","timestamp":1778581929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820311804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":52,"alternative-id":["S1043661820311804"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104872","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104872"}}